NaultJ-C, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
2.
BlacklowNR, HogganMD, SerenoMS, et al.A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol, 1971; 94:359–366.
3.
MayorHD, HoulditchGS, and MumfordDM. Influence of adeno-associated satellite virus on adenovirus-induced tumours in hamsters. Nat New Biol, 1973; 241:44–46.
4.
CukorG, BlacklowNR, KibrickS, et al.Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells. J Natl Cancer Inst, 1975; 55:957–959.
5.
OstroveJM, DuckworthDH, and BernsKI. Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus. Virology, 1981; 113:521–533.
6.
HermonatPL. Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product. Cancer Res, 1991; 51:3373–3377.
7.
ErlesK, SebökovàP, and SchlehoferJR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol, 1999; 59:406–411.
8.
de MartelC, Maucort-BoulchD, PlummerM, et al.World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology, 2015; 62:1190–1200.
9.
RajK, OgstonP, and BeardP. Virus-mediated killing of cells that lack p53 activity. Nature, 2001; 412:914–917.
10.
Georg-FriesB, BiederlackS, WolfJ, et al.Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology, 1984; 134:64–71.
11.
MayorHD, DrakeS, StahmannJ, et al.Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol, 1976; 126:100–104.
12.
HermonatPL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res, 1994; 54:2278–2281.
13.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
14.
RosasLE, GrievesJL, ZaraspeK, et al.Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther, 2012; 20:2098–2110.
15.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
16.
BellP, MoscioniAD, McCarterRJ, et al.Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther, 2006; 14:34–44.
17.
LiH, MalaniN, HamiltonSR, et al.Assessing the potential for AAV vector genotoxicity in a murine model. Blood, 2011; 117:3311–3319.
18.
NicholsTC, WhitfordMH, ArrudaVR, et al.Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev, 2015; 26:5–14.
19.
LiS, LingC, ZhongL, et al.Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol Ther, 2015 [Epub ahead of print]; DOI: 10.1038/mt.2015.174.
20.
HastieE, and SamulskiRJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success—a personal perspective. Hum Gene Ther, 2015; 26:257–265.
